Skip to main content

Chronic Lymphocytic Leukemia

Featured Article
“New treatments that delay disease progression in patients with hematologic cancer could have a significant impact on the economic burden of hematologic malignancies,” researchers wrote.
By preemptively looking for patients with chronic lymphocytic leukemia (CLL) who are most likely to not respond to therapy with Bruton's tyrosine kinase (BTK) inhibitors in the long-term, or who will…
Back to Top